CALGB40503_2B | R Documentation |
Kaplan-Meier digitized data from CALGB40503, figure 2B (PMID 27138575). A reported sample size of 350 for a primary endpoint of PFS in breast cancer.
CALGB40503_2B
A data frame of 343 observations and 3 variables:
time | event time (in months) | |
event | OS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (l, l_b) | |
Dickler MN, Barry WT, Cirrincione CT, et al. Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). J Clin Oncol 2016; 34: 2602–9.
summary(CALGB40503_2B)
kmplot(CALGB40503_2B)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.